AIMT

Aimmune Therapeutics

Last Updated:

Q1' 20

Price

quotes and stock data delayed 15 minutes

Cash

$358.4M

Burn Rate (Qtr)

-$69.2M

Company Profile

Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

AR101 (Palforzia)

Peanut Allergy

Quarterly Sales (Approved)

TBD

PALFORZIA®

Peanut Allergy | POSEIDON

Phase 3 (Data)

TBD

AR201

Egg Allergy

Phase 2 (Data)

H1 2021

Tree Nut

Multi-Tree Nut Allergy

Pre-Clinical

TBD

Recent Posts

See what the community is saying - click to see full post

AIMT - Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.

AIMT - Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science

Jackpot

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon